Peptide education
Insulin analogs
Insulin analogues
Insulin analogs are a group of modified insulin medicines used to lower blood glucose. They include different mealtime and background insulins, not one peptide or a single treatment plan.
Lispro, aspart, and glulisine are examples of rapid-acting analogs. Glargine, degludec, detemir, and icodec are basal analogs with product-specific instructions and availability.
Overview
Quick answer
A medicine's insulin molecule, concentration, device, and schedule all matter. A product strength is not a recommended dose, and a switch should be managed with the prescribing clinician.
What does U-100 or U-200 mean?
U-100 means 100 insulin units per milliliter; U-200 means 200 units per milliliter. These describe concentration, not how many units a person should take.
Are all insulin pens or pumps interchangeable?
No. Humalog U-100 can be used in a compatible pump, but Humalog U-200 cannot. The Tresiba label says not to use it in a pump.
Is every basal insulin taken daily?
No. Awiqli is a once-weekly insulin icodec-abae product for adults and children aged 10 years and older with type 2 diabetes. Its schedule differs from daily basal products.
What is the most important immediate risk?
Severe hypoglycemia can cause seizures, loss of consciousness, or death. Product, dose, or schedule errors can cause severe harm.
Evidence
Evidence snapshot
A randomized study compared glargine with NPH insulin added to oral therapy in type 2 diabetes.
Glargine versus NPH participants reaching HbA1c at or below 7% without documented nocturnal hypoglycemia in that study.
The products discussed have different insulin strengths. Concentration is not a dose or an instruction to convert between products.
Severe low glucose can occur with any insulin and requires urgent attention.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| All insulin analogs work on the same schedule. | Humalog is a rapid-acting mealtime insulin, while Lantus is a basal product and Awiqli is a once-weekly basal product for eligible adults and children aged 10 years and older with type 2 diabetes. | Molecule and formulation determine the product instructions. |
| A higher concentration always means a higher prescribed number of insulin units. | U-100 and U-200 describe units per milliliter. The Humalog pen's dose window displays the units to be delivered without a manual conversion. | Concentration and prescribed dose are different concepts. |
| The glargine trial proves every analog prevents nighttime hypoglycemia. | The study compared glargine with NPH in adults with type 2 diabetes; low glucose remained possible with insulin treatment. | Do not extend one comparison to the entire group. |
Bottom line
Main takeaway
Confirm the prescribed insulin name, strength, and device before each use.
Severe hypoglycemia can be life-threatening; discuss recognition and an emergency plan with the care team.
The glargine result is a 24-week comparison with NPH in a particular type 2 diabetes population.
Identity
What it is
Rapid-acting and basal insulin analogs serve different roles. Their labels describe different concentrations, devices, and routes.
The examples below are not an exhaustive list of insulin medicines or formulations. An individual product label determines its approved use.
Use context
Routes, doses, and cycle patterns
Insulin labels specify the molecule, concentration, route, and device. Changes between products can affect glucose control and need close monitoring.
Human studies and product labels
Insulin lispro, Humalog
- Purpose
- Rapid-acting insulin for glucose control in adults and pediatric patients with diabetes
- Context
- U.S. prescription label
- Route
- Subcutaneous; U-100 has additional labeled routes
Humalog is labeled as U-100 and U-200. Only U-100 is allowed in a compatible pump; U-200 must not be transferred from its pen to a syringe.
Insulin aspart, NovoLog
- Purpose
- Rapid-acting insulin for glucose control in adults and pediatric patients with diabetes
- Context
- U.S. prescription label
- Route
- Subcutaneous; the label also describes intravenous use
NovoLog is a U-100 product. Pump use depends on the product and pump instructions.
Insulin glulisine, Apidra
- Purpose
- Rapid-acting insulin for glucose control in adults and pediatric patients with diabetes
- Context
- U.S. prescription label
- Route
- Subcutaneous; the label also describes intravenous use
Apidra is labeled as U-100. The device and route must follow its own instructions.
Insulin glargine, Lantus and Toujeo
- Purpose
- Long-acting basal insulin for glucose control
- Context
- U.S. prescription labels
- Route
- Subcutaneous
Lantus is U-100 and Toujeo is U-300. Both contain glargine, but their labels describe different responses and switching instructions. Toujeo is labeled for adults and children aged 6 years and older.
Insulin degludec, Tresiba
- Purpose
- Long-acting basal insulin for glucose control
- Context
- U.S. prescription label
- Route
- Subcutaneous
Tresiba is available as U-100 and U-200 and is indicated for patients aged 1 year and older. For children needing less than 5 units daily, the label specifies the U-100 vial. Tresiba is not for pump or intravenous use.
Insulin detemir, Levemir
- Purpose
- Long-acting basal insulin for glucose control
- Context
- U.S. product listing and label
- Route
- Subcutaneous
The cited Levemir label describes U-100. Its product listing records marketing end dates for the listed U.S. presentations; confirm current availability.
Insulin icodec-abae, Awiqli
- Purpose
- Basal insulin for glucose control in adults and children aged 10 years and older with type 2 diabetes
- Context
- U.S. prescription label
- Route
- Subcutaneous
- Frequency
- Once weekly
Awiqli is U-700 and is not a daily basal insulin. The label warns that product mix-ups and frequency errors have caused serious hypoglycemia.
What varies
- Concentration: units per mL identify the formulation, not the number of units prescribed.
- Switching: changes in type, strength, manufacturer, or delivery method require medical supervision and closer glucose monitoring.
- Devices: never share insulin pens, needles, or syringes, even if a needle is changed.
Research
Research evidence
Human studies and U.S. labels support specific insulin products. One glargine trial illustrates a comparison with NPH, not a class-wide result.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Glargine versus NPH added to oral therapy | 756 overweight adults with type 2 diabetes inadequately controlled on oral medicines | Randomized, open-label, 24-week trial | Basal insulin glargine versus NPH alongside oral therapy | HbA1c at or below 7% without documented nocturnal hypoglycemia was reached by 33.2% versus 26.7%, respectively. Mean HbA1c was similar. | The results do not compare all analogs, concentrations, or diabetes populations. | Strong |
| Awiqli adult type 2 diabetes trials | Adults with type 2 diabetes in product-label clinical studies | Randomized active-controlled studies | Once-weekly insulin icodec-abae compared with daily basal insulin | The FDA label reports changes in HbA1c in several distinct trials. | These studies do not establish a universal conversion or support extending the labeled indication to all patients. | Strong |
| Awiqli pediatric pharmacokinetic study | 18 children and adolescents aged 10 years and older with type 2 diabetes | Single-dose pharmacokinetic study with modeling and adult study evidence | Subcutaneous insulin icodec-abae | The FDA reported faster initial absorption in pediatric patients. Modeling predicted blood levels similar to adults after the first few doses. | The pediatric study measured drug levels after one dose, not long-term glucose outcomes. | Pediatric pharmacokinetic data |
Cautions
Safety and unknowns
- Severe hypoglycemia can cause seizures, unconsciousness, or death. The risk changes with meals, activity, illness, other medicines, and kidney or liver impairment.
- Awiqli medication and frequency errors have led to serious hypoglycemia; its long action may delay recovery compared with shorter-acting insulins.
- Insulin can cause low potassium, allergic reactions, and injection-site changes. Pump failure can cause high glucose and ketoacidosis.
- Thiazolidinediones taken with insulin can cause fluid retention and worsen or lead to heart failure.
Product quality
Product identity and quality
The cited evidence concerns named prescription products. A molecule name alone does not identify the concentration or delivery device.
Name and strength
Lantus and Toujeo both contain glargine but have different concentrations and switching instructions.
Device compatibility
Humalog U-200 must not be used in a pump or transferred from its pen into a syringe.
Mechanism
How it is proposed to work
Insulin activates its receptor and helps lower glucose in the blood.
Insulin promotes glucose uptake in muscle and fat and reduces glucose production by the liver. Product design alters its time course.
FAQ
Common questions
Does U-200 mean twice the prescribed insulin dose?
No. U-200 describes a concentration of 200 insulin units per milliliter, not a prescribed dose. Use the specific product and device instructions.
Can Humalog U-200 be used in an insulin pump?
No. The Humalog label permits U-100 in a compatible pump but says not to administer U-200 by pump.
Details
Technical details
Sources
References
- 1.
DailyMed. Humalog prescribing information
- 2.
DailyMed. NovoLog prescribing information
- 3.
DailyMed. Apidra prescribing information
- 4.
DailyMed. Lantus prescribing information
- 5.
DailyMed. Toujeo prescribing information
- 6.
DailyMed. Tresiba prescribing information
- 7.
- 8.
FDA-approved prescribing information. Awiqli prescribing information
- 9.
- 10.
doi:10.2337/diacare.26.11.3080 PMID:14578243